Small molecule hydrazide agents to inhibit growth and proliferation of mycobacterium tuberculosis

Medicinal Chemistry

Volumn 8, Issue 2, 2012, Pages 273-280

  Bartzatt, Ronald ^a   Cirillo, Suat L G ^b   Cirillo, Jeffrey D ^b  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Antibacterial; Hydrazide; Isoniazid; Mycobacterium; Tuberculosis; Tuberculostatic.

Indexed keywords

ANTIINFECTIVE AGENT; AROMATIC COMPOUND; HYDRAZIDE DERIVATIVE; ISONIAZID; PYRIDINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; ATOM; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIAL VIABILITY; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG PENETRATION; DRUG TARGETING; HUMAN; INTESTINE ABSORPTION; MOLECULAR MODEL; MOLECULAR WEIGHT; MYCOBACTERIUM TUBERCULOSIS; OPTICAL DENSITY; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 84861934387     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340612800493647     Document Type: Article

References (34)

1. Dumar, V.; Abbas, A.; Fausto, N.; Mitchell, R. Robbins Basic Pathology, 8th ed., Saunders Elsevier: New York, 2007
2. Jasmer, R.; Nahid, P.; Hopewell, P. Clinical practice. latent tuberculosis infection. N. Engl. J. Med., 2002, 347(23), 1860-66
3. Parish, T.; Stoker, N. Mycobacteria: bugs and bugbears (two steps forward and one step back). Mol. Biotechnol., 1999, 13(3), 191-200 (Pubitemid 30167346)
4. Agarwal, R.; Malhotra, P.; Awasthi, A.; Kakkar, N.; Gupta, D. Tuberculosis dilated cardiomyophathy: an under-recognized entity. BMC: Infect. Dis., 2005, 5(1), 29-32
5. Behr, M.; Warren, S.; Salamon, H.; Hopewell, P.; Ponce de Leon, A.; Daley, C.; Small, P. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet, 1999, 353 (9051), 444-49 (Pubitemid 29067335)
6. Comstock, G. The international tuberculosis campaign: a pioneering venture in mass vaccination and research. Clin. Infect. Dis., 1994, 19(3), 528-40
7. Kumar, S.; Keda, M.; Bagga, M.; Kala, M.; Gauthaman, K. A systematic review of different type of tuberculosis. Eur. Rev. Med. Pharmacol. Sci., 2010, 14(10), 831-43
8. Dye, C.; Floyd, K. Tuberculosis, 2nd ed., National Institute of Health: Washington (DC), 2006
9. Thamthitiwat, S.; Marin, N.; Baggett, H.; Peruski, L.; Kiatkulwiwat, W.; Panumatrasmee, V.; Varma, J.; Nateniyom, S.; Akarasewi, P.; Maloney, S. Mycobacterium bovis (Bacille Calmette-Guerin) bacteremia in immunocompetent neonates following vaccination. Vaccine, 2011, 29(9), 1727-30
10. Breed, R.S.; Murray, E.G.D.; Smith, N.R. Bergey's Manual of Determinative Bacteriology, 7th ed.; The Williams & Wilkins Company: Baltimore, 1957
11. Pasqualoto, K.F.; Ferreira, E.L.; Santos-Filho, O.A.; Hopfinger, A.J. Rational design of new antituberculosis agents: receptorindependent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives. J. Med. Chem., 2004, 47(15), 3755-64 (Pubitemid 38900342)
12. Davis, A.S.; Vergne, I.; Master, S.S.; Kyei, G.B.; Chua, J.; Deretic, V. Mechanism of inducible nitric oxide synthase exclusion from mycobacterial phagosomes. PLoS Pathogens, 2007, 3(12), e186
13. Deretic, V.; Pagan-Ramos, E.; Zhang, Y.; Dhandayuthapani, S.; Via, L.E. The extreme sensitivity of Mycobacterium tuberculosis to the front-line antituberculosis drug isoniazid. Nat. Biotechnol., 1996, 14(11), 1557-61 (Pubitemid 26365548)
14. Zhang, Y.; Dhandayuthapani, S.; Deretic, V. Molecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid. Proc. Natl. Acad. Sci. USA, 1996, 93(23), 13212-6 (Pubitemid 26382795)
15. Meyer, H.; Mally, J. On hydrazine derivatives of pyridine carbonic acids. Chem. Monthly, 1912, 33, 393-414
16. Timperio, A.M.; Rinalducci, S.; Zolla, L. Hydrazide derivatives produce active oxygen species as hydrazine. Bioorg. Chem., 2005, 33(6), 459-69 (Pubitemid 41674459)
17. Liu, C.; Li, H.; Li, L.; Hu, Y.; Wang, Q.; Yang, N.; Wang, S.; Zhu, B. Anti-tuberculosis drug resistance patterns and trends in a tuberculosis referral hospital, 1997-2009. Epidermiol. Infect., 2011, 139(12), 1909-18
18. Tomioka, H.; Tatano, Y.; Yasumoto, K.; Shimizu, T. Recent advances in antituberculous drug development and novel drug targets. Expert. Rev. Respir. Med., 2008, 2(4), 455-71
19. Fairlie, L.; Beylis, N.; Reubenson, G.; Moore, D.; Madhi, S. High prevalience of multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect. Dis., 2011, 11(1), 28-32
20. Sangare, L.; Diande, S.; Badoum, G.; Dingtourmda, B.; Traore, A. Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso. Int. J. Tuberc. Lung Dis., 2010, 14(11), 1424-29
21. Tang, S.; Zhang, Q.; Yu, J.; Liu, Y.; Sha, W.; Sun, H.; Fan, L.; Gu, J.; Hao, X.; Yao, L.; Xiao, H. Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: clinical characteristics and treatment outcomes. Scand. J. Infect. Dis., 2011, 43(4), 280-5
22. Nguyen, L.; Hamilton, C.; Xia, Q.; Stout, J. Mortality before or during treatment among tuberculosis patients in North Carolina, 1993-2003. Int. J. Tuberc.. Dis., 2011, 15(2), 257-62
23. Bartzatt, R.; Cirillo, S.L.; Cirillo, J. Four hydrazide compounds that inhibit the growth of Mycobacterium tuberculosis. Physiol. Chem. Phys. Med. NMR, 2008, 40, 55-65
24. Bartzatt, R.; Cirillo, S.L.; Cirillo, J. Determination of molecular properties effectuating the growth inhibition of Mycobacterium tuberculosis by various small molecule hydrazides. Let. Drug Des. Disc., 2008, 5(3), 162-67
25. Sycheva, T.P.; Pavlova, T.N.; Shchukina, M.N. Synthesis of isoniazid from 4-cyanopyridine. Pharm. Chem. J., 1972, 6(11), 696-8
26. Awasthi, S.; Rishishwar, P.; Rao, A.N.; Ganesan, K.; Malhotra, R.C. Synthesis, characterization and spectral studies of various newer long chain aliphatic Acid (2-hydroxy benzylidene and 1Hindol-3 ylmethylene) hydrazides as mosquito para-pheromones. J. Kor. Chem. Soc., 2007, 51(6), 506-12 (Pubitemid 351149200)
27. Bartzatt, R. Spectrophotometric and colorimetric methodology to detect and quantify hydrazide based chemotherapeutic drugs. Environ. Chem. An Indian J., 2010, 5(1), 1-6
28. Clark, D. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci., 1999, 88(8), 807-11
29. Lipinski, C.; Lombardo, B.; Dominy, B.; Feeney, P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev., 2001, 46, 3-26 (Pubitemid 33653411)
30. Pajouhesh, H.; Lenz, G. Medicinal chemical properties of successful central nervous system drugs. J. Am. Soc. Exp. NeuroTherap., 2005, 2, 541-53 (Pubitemid 41393264)
31. van de Waterbeemd, H.; Kansy, M. Hydrogen-bonding capacity and brain penetration. Chimia, 1992, 46, 299-303
32. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J.; Raevsky, O. Estimation of blood-brain crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Targt., 1998, 6, 151-65 (Pubitemid 29033982)
33. Veber, D.; Johnson, S.; Cheng, H.Y.; Smith, B.; Ward, K.; Kopple, K. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45, 2615-23 (Pubitemid 34595232)
34. Bow, S. Pattern Recognition, Marcel Dekker: New York, 1984.